US Edition
Published • loading... • Updated
Deal: Astrazeneca Invests $50 Billion in the Us
Summary by poslovni.hr
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
After Pfizer, AstraZeneca also agreed (over the weekend) to sell its medicines directly to patients on the TrumpRx platform, with a discount of up to 80% on the catalog price. In return, Astra will obtain a three-year exemption from US import tariffs, although the company has already announced an investment of $50 billion in manufacturing and R & D in the United States over the next five years.
As part of the agreement, the company also committed to investments in the US, culminating in a planned investment of $50 billion by 2030.
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
